Glaukos Corporation (GKOS) Revenue History
Annual and quarterly revenue from 2012 to present
GKOS Revenue Over Time (2012–2025)
GKOS Revenue Growth History
11 of 13 years with positive growth- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- +762.3%
- FY2014 revenue growth
- +117.6%
- FY2015 revenue growth
- +57.3%
- FY2016 revenue growth
- +59.5%
- FY2017 revenue growth
- +39.2%
- FY2018 revenue growth
- +13.8%
- FY2019 revenue growth
- +30.7%
- FY2020 revenue growth
- -5.1%
- FY2021 revenue growth
- +30.7%
- FY2022 revenue growth
- -3.8%
- FY2023 revenue growth
- +11.3%
- FY2024 revenue growth
- +21.9%
- FY2025 revenue growth
- +32.3%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $150.6M | +41.2% |
| Q4 2025 | $143.1M | +35.7% |
| Q3 2025 | $133.5M | +38.1% |
| Q2 2025 | $124.1M | +29.7% |
| Q1 2025 | $106.7M | +24.6% |
| Q4 2024 | $105.5M | +28.1% |
| Q3 2024 | $96.7M | +23.9% |
| Q2 2024 | $95.7M | +19.0% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2019)
GKOS's revenue distribution by segment and geography for fiscal year 2019
By Product/Segment
By Geography
GKOS Revenue Analysis (2012–2025)
Current Revenue & Growth
As of June 22, 2026, Glaukos Corporation (GKOS) generated trailing twelve-month (TTM) revenue of $551.3 million, reflecting explosive growth of +41.2% year-over-year. The most recent quarter (Q1 2026) recorded $150.6 million in revenue, up 5.2% sequentially.
Historical Growth Trajectory
GKOS's 5-year compound annual growth rate (CAGR) stands at +17.7%, indicating consistent double-digit revenue growth. The 3-year CAGR of +21.5% exceeds the 5-year average, indicating an acceleration in the most recent period. Glaukos Corporation's highest annual revenue of $507.4 million was recorded in 2025, an all-time high.
Revenue by Segment
GKOS's revenue is primarily driven by Glaucoma (97%), and Corneal Health (3%). With over half of revenue concentrated in Glaucoma, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ATRC (+15.0% YoY), NVCR (+8.5% YoY), and TNDM (-6.8% YoY) — GKOS has outperformed the peer group in revenue growth. Compare GKOS vs ATRC →
GKOS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GKOSCurrent | $551M | +41.2% | +17.7% | -17.1% | |
 ATRC | $535M | +15.0% | +20.9% | -0.6% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 TNDM | $1.0B | -6.8% | +15.3% | -7.7% | |
 INSP | $912M | +8.9% | +51.2% | 5.6% | |
 EW | $6.1B | +11.2% | +6.7% | 27.0% |
GKOS Historical Revenue Data (2012–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $507.4M | +32.3% | $393.2M | 77.5% | $-86,733,000 | -17.1% |
| 2024 | $383.5M | +21.9% | $289.5M | 75.5% | $-122,366,000 | -31.9% |
| 2023 | $314.7M | +11.3% | $239.1M | 76.0% | $-128,700,000 | -40.9% |
| 2022 | $282.9M | -3.8% | $213.9M | 75.6% | $-82,313,000 | -29.1% |
| 2021 | $294.0M | +30.7% | $227.4M | 77.3% | $-32,872,000 | -11.2% |
| 2020 | $225.0M | -5.1% | $133.2M | 59.2% | $-123,553,000 | -54.9% |
| 2019 | $237.0M | +30.7% | $198.4M | 83.7% | $-50,292,000 | -21.2% |
| 2018 | $181.3M | +13.8% | $156.2M | 86.2% | $-13,002,000 | -7.2% |
| 2017 | $159.3M | +39.2% | $138.2M | 86.8% | $-2,281,000 | -1.4% |
| 2016 | $114.4M | +59.5% | $98.2M | 85.9% | $4.2M | 3.7% |
| 2015 | $71.7M | +57.3% | $58.7M | 81.9% | $-10,296,000 | -14.4% |
| 2014 | $45.6M | +117.6% | $34.2M | 75.0% | $-13,171,000 | -28.9% |
| 2013 | $20.9M | +762.3% | $18.4M | 87.9% | $-14,198,000 | -67.8% |
| 2012 | $2.4M | - | $774K | 31.9% | $-22,098,000 | -909.8% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
GKOS — Frequently Asked Questions
Quick answers to the most common questions about buying GKOS stock.
Is GKOS's revenue growth accelerating or slowing?
GKOS revenue growth is accelerating. TTM revenue reached $551M, up +41.2% year-over-year — ahead of the 5-year CAGR of +17.7%. This indicates the business is expanding faster than its historical baseline.
What is GKOS's revenue history from 2012 to 2026?
Glaukos Corporation (GKOS) revenue history spans 2012 to 2026. TTM revenue as of 2026 is $551M, growing at +41.2% YoY. The 5-year CAGR is +17.7%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is GKOS's long-term revenue growth rate (CAGR)?
Glaukos Corporation's 5-year revenue CAGR of +17.7% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +41.2% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for GKOS.
Why does GKOS's quarterly revenue fluctuate?
GKOS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Glaukos Corporation's revenue data from 2012 to 2026 shows full historical quarterly detail on this page.
How is GKOS's revenue distributed by segment?
GKOS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does GKOS's revenue compare to industry peers?
Glaukos Corporation (GKOS) with TTM revenue of $551M and +41.2% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.